Liver cirrhosis and antibiotic therapy but not TIPS application leads to a shift of the intestinal bacterial communities: A controlled, prospective study

J Dig Dis. 2024 Mar;25(3):200-208. doi: 10.1111/1751-2980.13262. Epub 2024 Apr 10.

Abstract

Objectives: The gut-liver axis is discussed to play an important role in hepatic cirrhosis. Decompensated liver cirrhosis is associated with portal hypertension, which can lead to a variety of complications. Transjugular intrahepatic portosystemic shunt (TIPS) is an established treatment option for the complications of portal hypertension. In this study we focused on the effect of TIPS on intestinal microbial composition in cirrhotic patients.

Methods: Thirty patients with liver cirrhosis were compared to 18 healthy adults. Seventeen patients with cirrhosis and portal hypertension received a TIPS. Clinical characteristics, including age, sex, and liver function measured with a Child-Pugh score and model for end-stage liver disease score, were obtained. Intestinal microbial composition was assessed via 16S rRNA gene amplicon sequencing from stool probes before and after TIPS.

Results: TIPS led to a reduction of hepatic venous pressure gradient. However, TIPS did not cause a shift in the intestinal bacterial communities. Independent from the application of TIPS, antibiotic therapy was associated with a significant difference in the intestinal bacterial microbiota and also a reduced α-diversity. In addition, a significant difference was observed in the intestinal bacterial composition between patients with liver cirrhosis and healthy controls.

Conclusion: The presence of liver cirrhosis and the use of antibiotic therapy, but not the application of TIPS, were associated with a significant shift of the intestinal bacterial communities, showing a high impact on the microbiota of patients with liver cirrhosis.

Keywords: intestinal bacterial composition; liver cirrhosis; microbiota; transjugular intrahepatic portasystemic shunt.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents* / therapeutic use
  • Case-Control Studies
  • Feces / microbiology
  • Female
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Hypertension, Portal* / etiology
  • Liver Cirrhosis* / complications
  • Liver Cirrhosis* / microbiology
  • Male
  • Middle Aged
  • Portasystemic Shunt, Transjugular Intrahepatic*
  • Prospective Studies
  • RNA, Ribosomal, 16S / analysis
  • RNA, Ribosomal, 16S / genetics

Substances

  • Anti-Bacterial Agents
  • RNA, Ribosomal, 16S

Grants and funding